Epigenetics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Enzymes (DNA polymerase, Acetylases, DNA ligases, Methyltransferase, RNA ligases, Reverse Transcriptase, Others), By Instruments (Next Generation Sequencers, Mass Spectrometers, Sonicators, qPCRs, Others), By Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Inflammatory Diseases, Infectious Diseases), By Kits and Assays (Deep Sequencing Kit, Bisulfate Conversion Kit, Methyltransferase Assays, Chip- Seq Kits, Immunoprecipitation Kits, Histone Assay), By End-User (Pharmaceutical and Biotechnological Companies, Contract Research Companies, Academic and Research Institutes), and Region Forecast 2020-2031

Epigenetics Market size was valued at US$ 16.9 billion in 2024 and is expected to reach US$ 45.7 billion by 2031, growing at a significant CAGR of 15.3% from 2025-2031. Epigenetics is a study of heritable changes in gene expression which involves the change in phenotype without changing genotype, which in turn affects the reading of genes by cells. Epigenetic changes are natural and regular processes but are also influenced by various factors like lifestyle, environment, age, and state of disease. Epigenetic modifications can manifest a common manner of cells that differentiate terminally to end up as liver cells, skin cells, brain cells, etc.

Epigenetic change may have more damaging effects which can lead to diseases like cancer. Systems like histone modification, non-coding RNA-associated gene silencing, and DNA methylation are considered for the initiation of epigenetic change sustainably. In October 2016 Episode an epigenetics data company launched SEED a novel male fertility test to evaluate epigenetic changes on DNA to detect a risk of infertility and poor embryo development.

Key Developments

• On Sept. 04, 2024: QIAGEN announced that it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer’s disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping.
• On Aug. 28, 2024: QIAGEN announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies being developed to address chronic diseases.
• On February 24, 2025: Illumina, Inc. has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio was presented at the Advances in Genome Biology and Technology (AGBT) General Meeting.